Track record · closed signal

Boston Scientific Corporation (BSX) — closed signal from November 11, 2025

Partial Published before the outcome was known, scored automatically when the window closed on February 9, 2026.

Predicted vs. what happened

BSX price · publication thesis → realized outcomesplit-adjusted

$100.00 – $102.50Entry zone — fair-value band

$101.96Published — price the day we called it

$120.31Target — the price the thesis aimed for

$105.65Peak — highest point inside the window, not a realized return

$76.27Window close — end-of-window price, context only

What happened

Partial

Reached 20% of the predicted growth at its peak, without hitting the target.

Peak price

$105.65

peak on November 13, 2025 — not a realized return

Peak gain

+3.6%

peak, from the publication price

Window close

$76.27

end-of-window price, context only

Days to target

—

Window

November 11, 2025 – February 9, 2026

The thesis — published November 11, 2025

Predicted growth

+18%

over the measurement window

Target price

$120.31

the price the thesis aimed for

Entry zone

$100.00 – $102.50

the fair-value band we waited for

Price at publication

$101.96

published November 11, 2025

Confidence

64%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Boston Scientific looks like a steady grower with strong price momentum and upbeat investor mood. Recent research calls for profits per share to rise about 20.7%, and a respected value-and-growth model also favors it. We prefer buying small dips over the next 0-3 months while lots more people are buying than usual and the recent average price is climbing. New products and solid execution matter, but we will keep an eye on valuation.

Primary drivers

Buying interest is strong and the recent average price keeps rising
Investor mood is very upbeat and new products are rolling out steadily
Profits per share are expected to grow about 20.7%, a healthy pace
Respected screens like it, and analysts have nudged price targets up

How it played out

BSX: target was not reached

Lyra published BSX at $101.96 on 2025-11-11 with an 18% expected gain and a $120.31 target. The thesis pointed to strong buying interest, a rising recent average price, upbeat investor mood, steady product rollouts, expected profits per share growth of about 20.7%, and higher analyst price targets.

Inside the window, BSX peaked at $105.65 on 2025-11-13, a 3.6% gain. It stayed below the $120.31 target and never reached it. By 2026-02-09, it ended at $76.27. The published thesis missed.

What happened during the window

On 2026-01-15, Boston Scientific agreed to buy Penumbra for $14.5 billion in cash and stock. On 2026-02-04, Investors.com reported Boston Scientific fourth-quarter results and said shares fell after electrophysiology sales missed expectations.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All BSX signals